NVIDIA (NVDA) and Eli Lilly (LLY) announce co-innovation AI lab to reinvent drug discovery in the age of AI

• The two companies will invest up to USD 1bln in talent, infrastructure and compute over five years to support the new AI co-innovation lab.

The partnership between NVIDIA and Eli Lilly to establish a co-innovation AI lab represents a significant strategic move, with a planned investment of up to $1 billion in resources over five years. This collaboration could enhance Eli Lilly's drug discovery processes while boosting NVIDIA's position in the growing AI and healthcare sectors, potentially influencing investor sentiment in both equities and related industries.